![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight A new study from NEJM](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight A new study from NEJM
USD22.45
USD72.45
Pay in 4 interest-free payments of $5.61 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight A new study from NEJM](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3633213598699902937)
![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight A new study from NEJM](https://www.nejm.org/cms/asset/81f382f2-15dd-4803-8e97-aacae0303585/nejmoa2107519_f1.jpg)
![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight A new study from NEJM](https://medicaldialogues.in/h-upload/2024/02/26/233050-tirzepatide.webp)
![tirzepatide obesity nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight A new study from NEJM](https://www.nejm.org/cms/asset/01b1d3fc-578b-464e-bfe2-55fe16a74f42/nejmoa2410819_f1.jpg)
